Loading…
Loading…
PHAT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PHAT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PHAT and 80,000+ other tickers.
See exactly how PHAT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PHAT and 80,000+ other tickers.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination…
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults.
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts across gastroesophageal reflux disease (GERD), Helicobacter pylori (H. pylori) eradication, long-term safety, and post endoscopic procedural care, reflecting the growing scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class in GI medicine.